Sheldon H Preskorn

Summary

Publications

  1. ncbi Clinically relevant pharmacology of neuropsychiatric drugs approved over the last three years: Part II
    Sheldon H Preskorn
    Department of Psychiatry, University of Kansas School of Medicine-Wichita, Wichita, Kansas, USA
    J Psychiatr Pract 12:312-6. 2006
  2. ncbi Deconstructing a medication regimen
    Sheldon H Preskorn
    Department of Psychiatry, University of Kansas School of Medicine-Wichita, USA
    J Psychiatr Pract 14:114-8. 2008
  3. ncbi How multiple medication use evolves and the importance of therapeutic trials: the slippery slide
    Sheldon H Preskorn
    Department of Psychiatry, University of Kansas School of Medicine-Wichita, USA
    J Psychiatr Pract 14:170-5. 2008
  4. ncbi Comparison of the pharmacokinetics of venlafaxine extended release and desvenlafaxine in extensive and poor cytochrome P450 2D6 metabolizers
    Sheldon Preskorn
    Clinical Research Institute, Wichita, KS 67211, USA
    J Clin Psychopharmacol 29:39-43. 2009
  5. ncbi Effect of desvenlafaxine on the cytochrome P450 2D6 enzyme system
    Sheldon H Preskorn
    Clinical Research Institute and University of Kansas School of Medicine, Wichita, KS 67211, USA
    J Psychiatr Pract 14:368-78. 2008
  6. ncbi The potential for clinically significant drug-drug interactions involving the CYP 2D6 system: effects with fluoxetine and paroxetine versus sertraline
    Sheldon H Preskorn
    University of Kansas School of Medicine, Wichita, KS, USA
    J Psychiatr Pract 13:5-12. 2007
  7. ncbi An innovative design to establish proof of concept of the antidepressant effects of the NR2B subunit selective N-methyl-D-aspartate antagonist, CP-101,606, in patients with treatment-refractory major depressive disorder
    Sheldon H Preskorn
    Clinical Research Institute, Wichita, KS 67204, USA
    J Clin Psychopharmacol 28:631-7. 2008
  8. ncbi Comparison of duloxetine, escitalopram, and sertraline effects on cytochrome P450 2D6 function in healthy volunteers
    Sheldon H Preskorn
    Department of Psychiatry and Behavioral Sciences, University of Kansas School of Medicine, KS 67207, USA
    J Clin Psychopharmacol 27:28-34. 2007
  9. ncbi Outliers on the dose-response curve: how to minimize this problem using therapeutic drug monitoring, an underutilized tool in psychiatry
    Sheldon H Preskorn
    Department of Psychiatry, University of Kansas School of Medicine Wichita, and Chief Science Officer and Medical Director, Clinical Research Institute, Wichita, Kansas, USA
    J Psychiatr Pract 16:177-82. 2010
  10. ncbi Treatment options for the patient who does not respond well to initial antidepressant therapy
    Sheldon H Preskorn
    Department of Psychiatry, University of Kansas School of Medicine Wichita, Clinical Research Institute, Wichita, Kansas, USA
    J Psychiatr Pract 15:202-10. 2009

Collaborators

Detail Information

Publications55

  1. ncbi Clinically relevant pharmacology of neuropsychiatric drugs approved over the last three years: Part II
    Sheldon H Preskorn
    Department of Psychiatry, University of Kansas School of Medicine-Wichita, Wichita, Kansas, USA
    J Psychiatr Pract 12:312-6. 2006
  2. ncbi Deconstructing a medication regimen
    Sheldon H Preskorn
    Department of Psychiatry, University of Kansas School of Medicine-Wichita, USA
    J Psychiatr Pract 14:114-8. 2008
  3. ncbi How multiple medication use evolves and the importance of therapeutic trials: the slippery slide
    Sheldon H Preskorn
    Department of Psychiatry, University of Kansas School of Medicine-Wichita, USA
    J Psychiatr Pract 14:170-5. 2008
  4. ncbi Comparison of the pharmacokinetics of venlafaxine extended release and desvenlafaxine in extensive and poor cytochrome P450 2D6 metabolizers
    Sheldon Preskorn
    Clinical Research Institute, Wichita, KS 67211, USA
    J Clin Psychopharmacol 29:39-43. 2009
    ....
  5. ncbi Effect of desvenlafaxine on the cytochrome P450 2D6 enzyme system
    Sheldon H Preskorn
    Clinical Research Institute and University of Kansas School of Medicine, Wichita, KS 67211, USA
    J Psychiatr Pract 14:368-78. 2008
    ..Individuals with impaired CYP2D6 metabolism and those concomitantly receiving agents that inhibit CYP2D6 can have variations in concentrations of such medications and their metabolites...
  6. ncbi The potential for clinically significant drug-drug interactions involving the CYP 2D6 system: effects with fluoxetine and paroxetine versus sertraline
    Sheldon H Preskorn
    University of Kansas School of Medicine, Wichita, KS, USA
    J Psychiatr Pract 13:5-12. 2007
    ....
  7. ncbi An innovative design to establish proof of concept of the antidepressant effects of the NR2B subunit selective N-methyl-D-aspartate antagonist, CP-101,606, in patients with treatment-refractory major depressive disorder
    Sheldon H Preskorn
    Clinical Research Institute, Wichita, KS 67204, USA
    J Clin Psychopharmacol 28:631-7. 2008
    ....
  8. ncbi Comparison of duloxetine, escitalopram, and sertraline effects on cytochrome P450 2D6 function in healthy volunteers
    Sheldon H Preskorn
    Department of Psychiatry and Behavioral Sciences, University of Kansas School of Medicine, KS 67207, USA
    J Clin Psychopharmacol 27:28-34. 2007
    ..Compared with sertraline, duloxetine produced statistically significantly larger changes in metoprolol pharmacokinetic parameters. The changes produced by escitalopram and sertraline were not statistically different...
  9. ncbi Outliers on the dose-response curve: how to minimize this problem using therapeutic drug monitoring, an underutilized tool in psychiatry
    Sheldon H Preskorn
    Department of Psychiatry, University of Kansas School of Medicine Wichita, and Chief Science Officer and Medical Director, Clinical Research Institute, Wichita, Kansas, USA
    J Psychiatr Pract 16:177-82. 2010
    ..Examples of each of these types of drugs are cited...
  10. ncbi Treatment options for the patient who does not respond well to initial antidepressant therapy
    Sheldon H Preskorn
    Department of Psychiatry, University of Kansas School of Medicine Wichita, Clinical Research Institute, Wichita, Kansas, USA
    J Psychiatr Pract 15:202-10. 2009
    ..The goal of this column to summarize the data supporting various options for the busy clinician who treats such patients...
  11. ncbi CNS drug development. Part I: The early period of CNS drugs
    Sheldon H Preskorn
    Department of Psychiatry, University of Kansas School of Medicine Wichita, Wichita, Kansas, USA
    J Psychiatr Pract 16:334-9. 2010
    ..The impact of the blockbuster business model and modern marketing/sales approaches on CNS drug development is also discussed...
  12. ncbi Complexity of medication use in the Veterans Affairs healthcare system: Part II. Antidepressant use among younger and older outpatients
    Beryl Silkey
    Via Christi Research Institute, Wichita, KS, USA
    J Psychiatr Pract 11:16-26. 2005
    ..This fact is a particular concern with psychiatric medications because adverse DDIs involving these medications can mimic psychiatric symptoms and may therefore be more difficult to detect...
  13. ncbi Phase I trials: from traditional to newer approaches. Part I
    Matthew Macaluso
    Department of Psychiatry and Behavioral Sciences, University of Kansas School of Medicine Wichita, KS, USA
    J Psychiatr Pract 17:200-3. 2011
    ..The second half of the series will propose modifications to the traditional phase I design, including the incorporation of different populations, bio-marker surrogates, and adaptive designs...
  14. ncbi How sequential studies inform drug development: evaluating the effect of food intake on optimal bioavailability of ziprasidone
    Jana Lincoln
    Clinical Research Institute and Kansas University School of Medicine Wichita, 1010 N Kansas, Wichita, KS 67217, USA
    J Psychiatr Pract 16:103-14. 2010
    ..These four studies illustrate the sequential and incremental nature of drug development research and what is meant by the concept of bioequivalence...
  15. ncbi How and why study designs affect the nature and validity of study results: appearance versus true knowledge. Part II
    Sheldon H Preskorn
    Department of Psychiatry, University of Kansas School of Medicine Wichita, and Chief Executive Officer and Medical Director, Clinical Research Institute, Wichita, Kansas, USA
    J Psychiatr Pract 15:402-7. 2009
    ..Journal of Psychiatric Practice 2009;15:402-407)...
  16. ncbi Drug-drug interactions: Proof of relevance (Part II): cause of tolerability problems or noncompliance
    Sheldon H Preskorn
    Department of Psychiatry, University of Kansas School of Medicine-Wichita, Wichita, Kansas, USA
    J Psychiatr Pract 11:397-401. 2005
  17. ncbi Drugs are an acquired source of biological variance among patients
    Sheldon H Preskorn
    Department of Psychiatry, University of Kansas School of Medicine-Wichita, Wichita, Kansas, USA
    J Psychiatr Pract 12:391-6. 2006
  18. ncbi How biomarkers will change psychiatry. Part II: Biomarker selection and potential inflammatory markers of depression
    Matthew Macaluso
    Department of Psychiatry and Behavioral Sciences, University of Kansas School of Medicine Wichita, and KU Wichita Clinical Trials Unit, USA
    J Psychiatr Pract 18:281-6. 2012
    ....
  19. ncbi Antidepressant treatment and altered CYP2D6 activity: are pharmacokinetic variations clinically relevant?
    Inna D'Empaire
    University of Kansas School of Medicine, Wichita, KS 67206, USA
    J Psychiatr Pract 17:330-9. 2011
    ..e., phenoconversion), the pharmacokinetics, and hence the effects, of CYP2D6 substrate antidepressants can be altered...
  20. ncbi Coadministration of nefazodone and desipramine: a pharmacokinetic interaction study
    Ahsan Y Khan
    University of Kansas School of Medicine Wichita, Department of Psychiatry and Behavioral Sciences, 1010 North Kansas Street, Wichita, KS 67214, USA
    J Pak Med Assoc 57:230-5. 2007
    ..To determine the potential for pharmacokinetic interaction between nefazodone (NFZ), and desipramine (DMI)...
  21. ncbi Complexity of medication use in the Veterans Affairs healthcare system: Part I: Outpatient use in relation to age and number of prescribers
    Sheldon H Preskorn
    University of Kansas School of Medicine, Wichita, KS 27214, USA
    J Psychiatr Pract 11:5-15. 2005
    ..In addition, DDIs may present in this population in ways that mimic worsening of primary symptoms, which may lead to increased doses of the medication that is actually responsible for the problem, causing still more toxicity...
  22. ncbi The evolution of antipsychotic drug therapy: reserpine, chlorpromazine, and haloperidol
    Sheldon H Preskorn
    Department of Psychiatry, University of Kansas School of Medicine-Wichita, KS, USA
    J Psychiatr Pract 13:253-7. 2007
  23. ncbi Polypharmacy: when is it rational?
    Sheldon H Preskorn
    University of Kansas School of Medicine Wichita, Clinical Research Institute, Wichita, KS 67211, USA
    J Psychiatr Pract 13:97-105. 2007
    ..The authors then present a list of 10 criteria to guide the rational use of psychotropic polypharmacy and explain each in detail with examples drawn from clinical practice...
  24. ncbi Clinical and demographic factors associated with DSM-IV melancholic depression
    Ahsan Y Khan
    University of Kansas School of Medicine Wichita, Department of Psychiatry, Wichita, KS, USA
    Ann Clin Psychiatry 18:91-8. 2006
    ..The purpose of this paper is to use demographic and clinical data from a large diverse group of outpatients diagnosed with non-psychotic major depression to investigate the validity of the DSM-IV concept of melancholic depression...
  25. ncbi Phase I trials: from traditional to newer approaches part II
    Matthew Macaluso
    Department of Psychiatry and Behavioral Sciences, University of Kansas School of Medicine Wichita, KS, USA
    J Psychiatr Pract 17:277-84. 2011
    ..Adaptive trial designs and biomarker endpoints are discussed...
  26. ncbi CNS drug development: Part II: Advances from the 1960s to the 1990s
    Sheldon H Preskorn
    Department of Psychiatry, University of Kansas School of Medicine Wichita, Wichita, Kansas, USA
    J Psychiatr Pract 16:413-5. 2010
    ..The next column in this series will review CNS drug development during the first decade of the 21st century and discuss what directions we can expect the field to take in the next 10 to 20 years...
  27. ncbi Clinically important differences in the pharmacokinetics of the ten newer "atypical" antipsychotics: part 1
    Sheldon H Preskorn
    Department of Psychiatry, University of Kansas School of Medicine Wichita, KS, USA
    J Psychiatr Pract 18:199-204. 2012
    ....
  28. ncbi Clinically relevant pharmacology of neuropsychiatric drugs approved over the last three years: part I
    Sheldon H Preskorn
    Department of Psychiatry, University of Kansas School of Medicine-Wichita, KS, USA
    J Psychiatr Pract 12:244-9. 2006
  29. ncbi CNS drug development: part III: future directions
    Sheldon H Preskorn
    Department of Psychiatry, University of Kansas School of Medicine Wichita, and Chief Science Officer and Medical Director, Clinical Research Institute, Wichita, Kansas, USA
    J Psychiatr Pract 17:49-52. 2011
    ..We are at the beginning of an era when it is likely that the way in which CNS drugs are developed will need to be rethought, which will call for flexibility and creativity on the part of both drug developers and clinical researchers...
  30. ncbi Inadvertent fatal imipramine poisoning of a child: what happened to Tommy?
    Sheldon H Preskorn
    Department of Psychiatry, University of Kansas School of Medicine Wichita, Wichita, Kansas, USA
    J Psychiatr Pract 17:118-23. 2011
    ....
  31. ncbi The difference between the formal and the functional dose: the case of the patient on thioridazine and fluvoxamine
    Sheldon H Preskorn
    Department of Psychiatry, University of Kansas School of Medicine, Wichita, KS, USA
    J Psychiatr Pract 11:192-6. 2005
  32. ncbi Comments on the role of therapeutic drug monitoring for clozapine
    Sheldon H Preskorn
    Department of Psychiatry, School of Medicine, University of Kansas-Wichita, 1010 North Kansas Street, Wichita, KS 67214, USA
    J Psychiatr Pract 11:340-3. 2005
  33. ncbi Twenty percent of a representative sample of patients taking bupropion have abnormal, asymptomatic electroencephalographic findings
    Matthew Macaluso
    Department of Psychiatry and Behavioral Sciences, University of Kansas School of Medicine Wichita, Wichita, KS 67214, USA
    J Clin Psychopharmacol 30:312-7. 2010
    ..The presence of these waveforms in individuals taking a medication known to lower the seizure threshold may be a risk factor for developing seizures...
  34. ncbi What do the terms "drug-specific response/remission rate" and "placebo" really mean?
    Sheldon H Preskorn
    Department of Psychiatry, University of Kansas School of Medicine Wichita, Wichita, Kansas, USA
    J Psychiatr Pract 17:420-4. 2011
    ..That finding is consistent with the concept that there are likely many forms of depressive illness, only a fraction of which are responsive to drugs that work via effects on biogenic amines...
  35. ncbi How drug-drug interactions can impact managed care
    Sheldon H Preskorn
    Department of Psychiatry and Behavior Sciences, University of Kansas, School of Medicine, and Psychiatric Research Institute, Wichita, USA
    Am J Manag Care 10:S186-98. 2004
    ..In this paper, antidepressants and SSRIs in particular were used to illustrate these important points...
  36. ncbi Clinical application of the concept of relative potency: an example involving chlorpromazine and haloperidol
    Sheldon H Preskorn
    Department of Psychiatry, University of Kansas School of Medicine, Wichita, USA
    J Psychiatr Pract 11:258-61. 2005
  37. ncbi Neuroscience basis of clinical depression: implications for future antidepressant drug development
    Sheldon H Preskorn
    Department of Psychiatry, University of Kansas School of Medicine Wichita, KS, USA
    J Psychiatr Pract 15:125-32. 2009
    ..The goal of the column is to help clinicians better conceptualize the nature of depressive illness and its treatment and educate their patients about these issues...
  38. ncbi Examining concentration-dependent toxicity of clozapine: role of therapeutic drug monitoring
    Ahsan Y Khan
    Department of Psychiatry and Behavioral Sciences, School of Medicine, University of Kansas-Wichita, 1010 North Kansas Street, Wichita, KS 67214, USA
    J Psychiatr Pract 11:289-301. 2005
    ..Finally, the authors present four cases illustrating the issues involved and how TMD can be used to improve clinical care of patients being treated with clozapine, both in terms of improving efficacy and minimizing potential toxicity...
  39. ncbi Single enantiomer drugs: should they be developed?
    Ahsan Y Khan
    Outpatient Clinic, Department of Psychiatry and Behavioral Sciences, University of Kansas School of Medicine, Wichita, USA
    Essent Psychopharmacol 7:15-23. 2006
    ....
  40. ncbi Pharmacokinetics and therapeutics of acute intramuscular ziprasidone
    Sheldon H Preskorn
    Department of Psychiatry, University of Kansas School of Medicine-Wichita and the Clinical Research Institute, Wichita, Kansas 67212, USA
    Clin Pharmacokinet 44:1117-33. 2005
    ....
  41. ncbi Pharmacogenomics, informatics, and individual drug therapy in psychiatry: past, present and future
    Sheldon H Preskorn
    Clinical Research Institute, Psychiatry Department, University of Kansas School of Medicine-Wichita, Wichita, KS 67214, USA
    J Psychopharmacol 20:85-94. 2006
    ..That will change in the future with a better understanding of the pathophysiology of psychiatric illnesses which in turn will lead to improved therapies and the potential for more rationally derived combination treatments...
  42. ncbi Clinically important differences in the pharmacokinetics of the ten newer "atypical" antipsychotics: Part 2. Metabolism and elimination
    Sheldon H Preskorn
    Department of Psychiatry, University of Kansas School of Medicine Wichita, Wichita, KS, USA
    J Psychiatr Pract 18:361-8. 2012
    ....
  43. ncbi Rational use of multiple medications in medicine and psychiatry: a dimensional perspective
    Sheldon H Preskorn
    Department of Psychiatry, University of Kansas School of Medicine Wichita, Wichita, Kansas, USA
    J Psychiatr Pract 19:54-61. 2013
    ..g., such as are often used to treat bipolar disorder). By better understanding the principles involved in rational MMU, clinicians can optimize the treatment they provide their patients. (Journal of Psychiatric Practice 2013;19:54-61)...
  44. ncbi Why the transdermal delivery of selegiline (6 mg/24 hr) obviates the need for a dietary restriction on tyramine
    Sheldon H Preskorn
    Department of Psychiatry, University of Kansas School of Medicine-Wichita, KS, USA
    J Psychiatr Pract 12:168-72. 2006
  45. ncbi Drug-drug interactions: proof of relevance (part I)
    Sheldon H Preskorn
    Department of Psychiatry, University of Kansas School of Medicine-Wichita, and Clinical Research Institute, Wichita, Kansas, USA
    J Psychiatr Pract 11:116-22. 2005
  46. ncbi Multiple medication use presenting as Parkinson's dementia complex: a message from Titanic
    Sheldon H Preskorn
    Department of Psychiatry, University of Kansas School of Medicine-Wichita, Kansas, USA
    J Psychiatr Pract 14:45-54. 2008
  47. ncbi Neuroleptic malignant syndrome resulting from a complex drug-drug interaction: "I don't see 'em!"
    Sheldon H Preskorn
    Department of Psychiatry, University of Kansas School of Medicine-Wichita, Kansas, USA
    J Psychiatr Pract 13:328-33. 2007
  48. ncbi Mania in a case of polypsychopharmacology: pharmacodynamic and pharmacokinetic considerations. Do you believe in magic?
    Sheldon H Preskorn
    Department of Psychiatry, University of Kansas School of Medicine Wichita, USA
    J Psychiatr Pract 13:178-83. 2007
  49. ncbi Milnacipran: a dual norepinephrine and serotonin reuptake pump inhibitor
    Sheldon H Preskorn
    Department of Psychiatry, University of Kansas School of Medicine-Wichita, USA
    J Psychiatr Pract 10:119-26. 2004
  50. ncbi Reboxetine: a norepinephrine selective reuptake pump inhibitor
    Sheldon H Preskorn
    Department of Psychiatry, University of Kansas School of Medicine-Wichita, USA
    J Psychiatr Pract 10:57-63. 2004
  51. ncbi Concurrent administration of donepezil HCl and risperidone in patients with schizophrenia: assessment of pharmacokinetic changes and safety following multiple oral doses
    Josephine F Reyes
    Clinical Pharmacology, Eisai Medical Research Inc, Ridgefield Park, NJ 07660, USA
    Br J Clin Pharmacol 58:50-7. 2004
    ..This open-label, multiple-dose trial investigated the effect of concurrent administration of donepezil HCl with risperidone on the pharmacokinetics (PK) and safety profiles of both drugs...
  52. ncbi Multiple medication use in patients seen in the veterans affairs healthcare system: so what?
    Sheldon H Preskorn
    Department of Psychiatry, University of Kansas School of Medicine Wichita, Kansas, USA
    J Psychiatr Pract 11:46-50. 2005
  53. ncbi Demonstration of the efficacy and safety of a novel substance P (NK1) receptor antagonist in major depression
    Mark S Kramer
    Merck Research Laboratories, West Point, PA, USA
    Neuropsychopharmacology 29:385-92. 2004
    ..Antidepressant actions have now been observed with two different highly selective NK(1) antagonists (aprepitant and L-759274). NK(1) antagonism is a replicated and generally well-tolerated antidepressant mechanism...
  54. ncbi Duloxetine
    Sheldon H Preskorn
    Department of Psychiatry, University of Kansas School of Medicine-Wichita, USA
    J Psychiatr Pract 10:375-85. 2004
  55. ncbi Classification of neuropsychiatric medications by principal mechanism of action: a meaningful way to anticipate pharmacodynamically mediated drug interactions (part II)
    Sheldon H Preskorn
    Department of Psychiatry, University of Kansas School of Medicine-Wichita, USA
    J Psychiatr Pract 10:177-81. 2004